Navigation Links
Alchemia Reports Preliminary Positive Efficacy Data From HyCAMP,Phase II Trial

fter the welfare of the patients and diligently collected the data for analysis in this trial.

    ENQUIRIES: Dr. Tracie Ramsdale

    Chief Executive Officer

    Alchemia Limited

    Tel: +61-7-3340-0200


    RELEASED BY:

    Ms Anna Whybird

    Phillips Group

    Tel: +61-7-3230-5000

About HyACT

HyACT(TM) is a proprietary delivery technology which utilises Hyaluronic acid (HA), to deliver and enhance the retention of anti-cancer drugs within tumours. The drug becomes entrapped in a matrix of HA which binds to HA receptors located on the tumour resulting in more of the drug being delivered to the tumour cells. In preclinical studies, the HyACT(TM) technology has demonstrated improved delivery of the drug to the tumour resulting in significantly reduced toxicity and increased efficacy and survival.

About Irinotecan

Irinotecan is widely used in the treatment of metastatic colorectal cancer, and is being evaluated in many other tumour types. Like most cytotoxics the use of irinotecan is restricted by its side effects, the most significant of which are diarrhoea and neutropenia, and limited activity in some patients. Sales of Pfizer's irinotecan (Camptosar(R) ) were US$903 million in 2006, and patent exclusivity for the drug expires in 2008 in the US and 2009 in the EU.

About HyCAMP(TM)

HyCAMP(TM) is a proprietary formulation of the anti-cancer drug irinotecan. Preclinical studies with HyCAMP(TM) demonstrated improved delivery of the drug to the tumour, resulting in increased efficacy and reduced toxicity. The phase II clinical trial was initiated to evaluate HyCAMP(TM) in patients with metastatic colorectal cancer.

CLINICAL APPENDIX

The following additional information is provided in accordance with the Code of Best Practice for ASX Reporting by Life Science Companies

    Trial Title        Randomised Phase II Trial of irinotecan with Hyaluronic

                       Acid (HyCAMP(T
'"/>




Page: 1 2 3 4 5 6 7

Related medicine technology :

1. Corgenix Reports New Clinical Data Correlating AtherOx Technology With Vascular Disease
2. Cobalis Reports Phase III Trial Results for PreHistin in Seasonal Allergic Rhinitis
3. Cosmo Pharmaceuticals Reports Positive Preliminary Phase II/III Data with Rifamycin MMX in Infectious Diarrhea
4. Cytos Biotechnology Reports Results from Phase IIa Study with CYT003-QbG10 in Patients Suffering from Atopic Dermatitis
5. Cytokinetics Reports Additional Clinical Trials Data for Ispinesib
6. The European Myeloma Platform Reports New Survival data for Revlimid Presented at the International Myeloma Workshop in Greece
7. Cytochroma Reports Positive Phase I Clinical Data for CTA018 Injection
8. Speedel Reports Successful SPP635 Phase IIa Trial in Hypertension
9. Columbia Laboratories Reports Positive Results from Multi-dose Pharmacokinetic Study of Vaginally-administered Lidocaine
10. CytRx Reports Promising Data from Its Open-Label Extension Clinical Trial of Arimoclomol in ALS
11. Affymax Reports Phase 2 Clinical Dose Ranging Results of Once-Per-Month Hematide for the Treatment of Anemia
Post Your Comments:
(Date:7/11/2014)... -- Australian drug delivery company, Phosphagenics Limited (ASX: POH; OTCQX: ... via a placement of A$16.3 million to institutional investors ... Asia and Australia ... (SPP) to be offered to existing shareholders.  The placement ... "This capital raising positions us strongly to ...
(Date:7/11/2014)... ALBANY, New York , July 11, 2014 /PRNewswire/ ... published by Transparency Market Research "Endoscopy Devices Market (Endoscopes, ... Analysis, Size, Share, Growth, Trends and Forecast, 2013-2019" the ... billion in 2012 and is expected to grow at ... reach an estimated value of USD 36.9 billion in ...
(Date:7/11/2014)... 11, 2014  Veran Medical Technologies, a ... the positive, cost-effective final results for the ... The SPiNPerc endobronchial percutaneous biopsy study results ... to biopsy when a traditional bronchoscopic method ... experience positive financial outcomes when more can ...
Breaking Medicine Technology:Phosphagenics' A$19.3 million Capital Raising 2Phosphagenics' A$19.3 million Capital Raising 3Global Endoscopy Devices Market is Expected to Reach USD 36.9 Billion by 2019: Transparency Market Research 2Global Endoscopy Devices Market is Expected to Reach USD 36.9 Billion by 2019: Transparency Market Research 3Global Endoscopy Devices Market is Expected to Reach USD 36.9 Billion by 2019: Transparency Market Research 4Global Endoscopy Devices Market is Expected to Reach USD 36.9 Billion by 2019: Transparency Market Research 5Global Endoscopy Devices Market is Expected to Reach USD 36.9 Billion by 2019: Transparency Market Research 6Veran Medical Publishes Lung Cancer Patient Management Study 2
... , , MOUNTAIN VIEW, Calif. ... announced the initiation of a Phase I clinical trial ... autoimmune diseases.  CCX168 is a highly potent and very ... a component of the body,s complement system and a ...
... , Jan. 28 , Net Sales of $1.11 ... period (an increase of 2.5% constant currency) , Diluted ... from the prior year period, and $1.12 adjusted, an increase of 12.0% ... of $4.10 billion for the full year represent a decrease of 0.6% ...
Cached Medicine Technology:ChemoCentryx Initiates Clinical Trial of CCX168, A Novel Small Molecule C5aR Antagonist for the Treatment of Inflammatory and Autoimmune Diseases 2ChemoCentryx Initiates Clinical Trial of CCX168, A Novel Small Molecule C5aR Antagonist for the Treatment of Inflammatory and Autoimmune Diseases 3ChemoCentryx Initiates Clinical Trial of CCX168, A Novel Small Molecule C5aR Antagonist for the Treatment of Inflammatory and Autoimmune Diseases 4Zimmer Reports Fourth Quarter and 2009 Financial Results 2Zimmer Reports Fourth Quarter and 2009 Financial Results 3Zimmer Reports Fourth Quarter and 2009 Financial Results 4Zimmer Reports Fourth Quarter and 2009 Financial Results 5Zimmer Reports Fourth Quarter and 2009 Financial Results 6Zimmer Reports Fourth Quarter and 2009 Financial Results 7Zimmer Reports Fourth Quarter and 2009 Financial Results 8Zimmer Reports Fourth Quarter and 2009 Financial Results 9Zimmer Reports Fourth Quarter and 2009 Financial Results 10Zimmer Reports Fourth Quarter and 2009 Financial Results 11Zimmer Reports Fourth Quarter and 2009 Financial Results 12Zimmer Reports Fourth Quarter and 2009 Financial Results 13Zimmer Reports Fourth Quarter and 2009 Financial Results 14Zimmer Reports Fourth Quarter and 2009 Financial Results 15Zimmer Reports Fourth Quarter and 2009 Financial Results 16Zimmer Reports Fourth Quarter and 2009 Financial Results 17Zimmer Reports Fourth Quarter and 2009 Financial Results 18Zimmer Reports Fourth Quarter and 2009 Financial Results 19Zimmer Reports Fourth Quarter and 2009 Financial Results 20Zimmer Reports Fourth Quarter and 2009 Financial Results 21Zimmer Reports Fourth Quarter and 2009 Financial Results 22Zimmer Reports Fourth Quarter and 2009 Financial Results 23Zimmer Reports Fourth Quarter and 2009 Financial Results 24Zimmer Reports Fourth Quarter and 2009 Financial Results 25Zimmer Reports Fourth Quarter and 2009 Financial Results 26Zimmer Reports Fourth Quarter and 2009 Financial Results 27
(Date:7/13/2014)... According to a new market research report "Heterogeneous ... GPU, DSP, connectivity), Technology Node (45nm-5nm), Application (Consumer, ... and Analysis to 2014-2020", published by MarketsandMarkets, the ... expected to reach $61.70 Billion by 2020, growing ... 2020. , Browse 71 market data Tables with ...
(Date:7/13/2014)... Athletes with a certain genetic make-up ... according to research presented today at the American Orthopaedic ... The research marks the first of its kind investigating ... physical events that occur after a head injury. ... in the (GT)n genotype were four times more likely ...
(Date:7/13/2014)... Fadhits.com is popular among worldwide women. Its ... beautiful. Recently, the company has announced its new selection ... more, all these outfits are available at discounted prices ... the supplier is now offering similar discounts for many ... has many other designs for sale, including flower girl ...
(Date:7/13/2014)... 2014 Wright & Schulte LLC has ... scheduled in July of 2015, in U.S. District Court, ... in the discovery process in the South Carolina ... presiding over the multidistrict litigation (MDL). The complaints pending ... individuals who allege that they took the statin medication ...
(Date:7/13/2014)... MI (PRWEB) July 13, 2014 If Dr. ... program he has just launched at http://www.HealthYourself101.com will ... visceral obesity. , Power has set out to provide ... ill effects that’s actually – dare we say it? – ... program,” says Power, “aims to engage the remote learner – ...
Breaking Medicine News(10 mins):Health News:Heterogeneous Mobile Processing & Computing Market Worth $61.70 Billion by 2020 – New Report by MarketsandMarkets 2Health News:Heterogeneous Mobile Processing & Computing Market Worth $61.70 Billion by 2020 – New Report by MarketsandMarkets 3Health News:Heterogeneous Mobile Processing & Computing Market Worth $61.70 Billion by 2020 – New Report by MarketsandMarkets 4Health News:Genetic Factors May Be Responsible for Slowing Concussion Recovery in Athletes 2Health News:Fadhits.com Announces a Special Offer on Elegant Quinceanera Dresses 2Health News:Lipitor Lawsuits Move Forward With Scheduling Of First Bellwether Trial 2Health News:Lipitor Lawsuits Move Forward With Scheduling Of First Bellwether Trial 3Health News:Lipitor Lawsuits Move Forward With Scheduling Of First Bellwether Trial 4Health News:Retired Ann Arbor Physician and Professor Wields New Media to Teach Health Science 2Health News:Retired Ann Arbor Physician and Professor Wields New Media to Teach Health Science 3Health News:Retired Ann Arbor Physician and Professor Wields New Media to Teach Health Science 4
... as a surprise to politicians and rights leaders alike, mainly ... of girls in the 0-6 years category is coming down ... feticide and nothing else. The problem is that we are ... the guilty," said Health Minister P.K. Sreemathy Thursday while speaking ...
... Southwestern Medical Center, working with mice, have shown how ... decrease the fearful response associated with reliving a traumatic ... a mild electrical shock – mice in the study ... place where it happened, a condition that could be ...
... found a breakthrough in the treatment of breast cancer ... therapies.// ,According to Professor Miles Prince from Melbourne's ... emission tomography (PET) would probably change the way breast ... (PET) scans to monitor breast cancer patients to find ...
... in UK, 40% Of Adults Cannot Manage Without Cell ... Stoke-on-Trent, who had conducted the research//, claimed that certain ... their cell phones. In his study on how students ... of the behaviors displayed, closely resembled symptoms of ‘pathological ...
... Richards marks the rapid increase in esophageal cancer cases in the ... cancer.// Only 16 % or around 2,200, of the 14,000-esophageal cancer ... years. ,There has been a 6-fold annual rise in the ... to experts. Rise in obesity cases has been the major cause. ...
... can be effective in cluster headaches as well, researchers ... pain signals, Dr. Peter Goadsby, professor of clinical neurology ... not as common as migraines and affect one in ... In the final analysis 69 patients were included. These ...
Cached Medicine News:Health News:Pre-Clinical Study Suggests How Steroid Can Reverse Post-Traumatic Stress 2Health News:Pre-Clinical Study Suggests How Steroid Can Reverse Post-Traumatic Stress 3Health News:Aussie Doctors Claim Breakthrough in Breast Cancer Treatment 2Health News:Rise in Esophageal Cancer is emphasized by Richards’ deat 2
Microsect Curette with increased cutting edge and modified shaft, 10"....
Bone Curette, 160 mm...
Endocrette Endocervical Curette is a stainless-steel curette with closed blade....
Kevorkian Endocervical Curette is a stainless-steel curette with a basket. It is narrow tipped for sampling without dilation....
Medicine Products: